PH1

Clinical trials for PH1 explained in plain language.

Never miss a new study

Get alerted when new PH1 trials appear

Sign up with your email to follow new studies for PH1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug aims to lower dangerous oxalate levels in rare kidney disease

Disease control Not yet recruiting

This study tests a new medicine, YOLT-203, in children and adults with primary hyperoxaluria type 1, a rare genetic condition that causes harmful oxalate buildup. The trial will compare YOLT-203 to a placebo over 6 months to see if it safely reduces oxalate levels in urine and bl…

Matched conditions: PH1

Phase: PHASE2 • Sponsor: YolTech Therapeutics Co., Ltd • Aim: Disease control

Last updated May 15, 2026 11:53 UTC

PH1

Get alerted when new PH1 trials appear

New drug aims to lower dangerous oxalate levels in rare kidney disease